Science and Technology board to meet the new favorite in the field of biopharmaceuticals, currently in the research project reached 8

Pharmaceutical Network Industry Dynamics: As we all know, the research and development of new drugs in biopharmaceutical enterprises usually has the characteristics of high investment, long cycle and high risk.
And the board in the listing system innovation, relax the requirements for the profitability of listed enterprises, so that it and biopharmaceutical enterprises innovation research and development cycle is long, large investment and early non-profit characteristics, for enterprises to open up a new financing path, which also makes the board favored by biopharmaceutical enterprises.
recently, the company has welcomed a new favorite in the field of biomedicine.
that Coxing Biopharmaceutical Co., Ltd. (hereinafter referred to as "Koxing Pharmaceuticals") has recently completed the second round of inquiries.
Koxing Pharmaceuticals' IPO is intended to raise 1,705 million yuan, mainly for drug production base expansion, research and development center upgrade construction, information management system upgrade construction, supplementary liquidity and other projects, sponsors and lead underwriters are CITIC Construction Investment.
public information shows that Kexing Pharmaceuticals was founded in 1997, mainly engaged in recombinant protein drugs and micro-ecological preparations research and development, production and sales.
company's main products include recombinant protein drug "recombinant human erythroid", "recombinant human interferon alpha1b" "recombinant human granulocyte stimulation factor", micro-ecological preparation drug "Cytobacteria tyrosine" and so on.
It is understood that The injection of Coxing Pharmaceuticals with recombinant human interferon alpha1b (Serokin) market share firmly in the top three in the country, recombinant human erythrotin injection (CHO cells) export volume and export volume for more than 10 consecutive years in the domestic first of its kind.
company has been profitable for nearly three years.
2017-2019, Coxing Pharmaceuticals achieved operating income of 616 million yuan, 891 million yuan and 1.191 billion yuan, respectively, while net profit achieved during the same period was 59.3916 million yuan, 94.1637 million yuan and 160 million yuan, respectively, showing good growth.
, Coxing Pharmaceuticals through internal training and the introduction of external talent, with a high-quality, highly educated, industry-experienced research and development team.
the company's current research and development staff of 167 people, according to its prospecto.
notable for the fact that sales costs are also rising year by year, behind its growing operating capital.
2017-2019, the company's sales expenses amounted to 328 million yuan, 468 million yuan and 647 million yuan, respectively.
, the sales expense rates for the same period were 53.2%, 52.56% and 54.35%, respectively, accounting for half of revenue.
industry points out that companies with high sales costs tend to be limited in other areas.
this can be seen in the company's research and development investment.
2017-2019, the company invested 32.3474 million yuan in research and development, 42.6768 million yuan and 46.1697 million yuan, respectively, according to the prospecto, a cumulative total of 121 million yuan in three years.
figure is twice the standard for determining the properties of the science board.
but as a percentage of revenue from research and development, the share has been declining, from 5.25 per cent, 4.79 per cent and 3.88 per cent, respectively, from 2017 to 2019.
Pharmaceuticals disclosed in its prospectaning that it is currently working on eight biopharmaceutical projects.
At the same time, the company adjusts its research and development strategy according to the pharmaceutical market environment, gradually reduces its investment in chemical drug research and development since the fourth quarter of 2019, focuses on the main channel of biopharmaceuticals with advanced technology precipitation, and adopts the product strategy combining deep tillage advantage technology with cutting-edge biotechnology, and plans the product line according to the "near-medium-term-long-term" stage, and will continue to increase investment in biopharmaceutical research and development innovation.
addition, the company is currently in the "antiviral, blood, cancer and immunity, degenerative diseases" and other fields have formed a unique advantage, products are exported to Brazil, the Philippines, Indonesia and other more than 20 countries.